ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

SoftBank Vision Fund makes 1st Japan investment with biotech firm

Aculys draws $59m as tech group diversifies portfolio beyond U.S. and China

SoftBank Group has been focusing more on smaller investments beyond the U.S. and China in its second Vision Fund. (Photo by Yoichi Iwata)

TOKYO -- SoftBank Group's Vision Fund has invested in a Japanese company for the first time, Nikkei has learned, as the tech investor accelerates a push for geographic diversity in its portfolio.

The Vision Fund led a 6.8 billion yen ($59.7 million) investment into Aculys Pharma, a biotech startup co-founded in January by Kazunari Tsunaba, the former president of the Japanese arm of Novartis.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more